ausblenden:
Schlagwörter:
PROGRAMMED DEATH-1; STRUCTURAL BASIS; CANCER-IMMUNOTHERAPY;
CRYSTAL-STRUCTURE; HUMAN PD-1; CELL; INHIBITORS; BLOCKADE; LIGANDS;
COMPLEXChemistry; antitumor agents; protein-protein interactions; PD-1; PD-L1; protein
structures;
Zusammenfassung:
The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.
